1. Home
  2. MDWD vs EDAP Comparison

MDWD vs EDAP Comparison

Compare MDWD & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.67

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.38

Market Cap

163.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
EDAP
Founded
2000
1979
Country
Israel
France
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.3M
163.4M
IPO Year
2013
1998

Fundamental Metrics

Financial Performance
Metric
MDWD
EDAP
Price
$16.67
$3.38
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$36.00
$2.00
AVG Volume (30 Days)
83.2K
40.3K
Earning Date
05-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$70,527,000.00
Revenue This Year
$48.88
N/A
Revenue Next Year
$35.08
$10.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.63
52 Week Low
$14.77
$1.21
52 Week High
$22.51
$5.05

Technical Indicators

Market Signals
Indicator
MDWD
EDAP
Relative Strength Index (RSI) 49.13 37.87
Support Level N/A $3.32
Resistance Level $18.71 $4.32
Average True Range (ATR) 0.80 0.33
MACD 0.03 -0.04
Stochastic Oscillator 63.08 32.41

Price Performance

Historical Comparison
MDWD
EDAP

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: